An official website of the United States government
Home
Name
Brigatinib
Alternate Names
Alunbrig
Abbreviations
None
Category
Chemotherapy
Subcategory
NSC Number
None
Primary Site
Lung
Histology
Non-small cell lung cancer (NSCLC)
Remarks
May 29, 2020: The FDA approved Brigatinib (Alunbrig) for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
4/28/2017: FDA granted an accelerated approval to brigatinib, trade name Alunbrig, for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
4/28/2017: FDA granted an accelerated approval to brigatinib, trade name Alunbrig, for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Coding
This drug should be coded
